NEWS

October 2010 By Zhenya Senyak Eileen Wiggins – Out of the blue Eileen Wiggins is a practical woman, straightforward, no nonsense. So when she started feeling tired most all the time and losing a little weight – not that she couldn’t afford to drop a few pounds here and there but for her age she… Read More »WHITE PAPER: NATURE, NURTURE, OR BOTH?

October 2010 SBio, based in Singapore, is working on a JAK2 Inhibitor for Myelofibrosis patients, SB1518. They have just been granted orphan drug designation from the European Commission. The European Commission is the executive body of the European Union, and has an orphan drug incentive program similar to the U.S. This development potentially expands the… Read More »SBIO GRANTED ORPHAN DESIGNATION FOR MYELOFIBROSIS DRUG

October 2010 The Indian Journal of Medical Research recently published an article reporting the prevalence of the JAK2 mutation among polycythemia vera, essential thrombocythemia and myelofibrosis patients at a clinic in northern India. The JAK2 mutation, a gene marker for the Myeloproliferative disorders, was discovered in 2005. To read the full article click here.

The September 2010 issue of Blood included an article on a new model for estimating risk of blood clot for a variety of cancer patients. Patients with the hematological malignancies lymphoma and multiple myeloma were included in the study along with hard tumor patients to develop a model by which doctors could better predict risk.… Read More »ASH PRESS RELEASE ON BLOOD CLOT RISK PREDICTION MODEL

September 2010 The Tri-County Polycythemia Vera Community Advisory Committee was formed as a result of the discovery of a cluster of Polycythemia Vera (PV) patients in Luzerne, Schuylkill and Carbon counties in Pennsylvania. Their role is in part to educate the community about PV. On September 22nd the Committee is hosting a meeting to allow… Read More »PENNSYLVANIANS MEETING SEPTEMBER 22ND TO GET EDUCATED ON PV

Like the MPD Foundation, the United Kingdom’s MPD-Support has a free newsletter available to patients and other members of the MPD community. To download their latest edition of MPD Life click here.

September 2010 The FDA has approved a special protocol for Incyte’s clinical trial for Polycythemia Vera patients. Their RESPONSE (Randomized, open label, multicenter phase III study of Efficacy and Safety in POlycythemia vera subjects who are resistant to or intolerant of hydroxyurea: JAK iNhibitor INC424 tablets verSus bEst available care) is expected to enroll approximately… Read More »INCYTE APPROVED BY FDA FOR SPECIAL PV PROTOCOL

TargeGen, producer of JAK2 inhibitor TG101348, was purchased on June 30 2010 by French pharmaceutical company Sanofi-Aventis. Sanofi-Aventis hopes to continue to develop drugs targeted at hematological malignancies. Clinical trials for TG101348 have completed enrollment. For the full press release click here.

The MPD Foundation is pleased to announce a Call for Proposals for its 2011 Challenge Grant Program. Worthy projects will advance the understanding of mechanisms of action in the MPD’s and/or contribute to accelerating the discovery and development of new treatments for MPD patients. The MPD Foundation is a private not-for-profit advocacy organization seeking to… Read More »ANNOUNCING CHALLENGE GRANT 2011

Each year the American Society of Hematology (ASH) hosts their annual convention, where researchers, doctors and organizations such as the MPD Foundation gather to discuss the ever changing world of blood disorders and learn about the progress of research. The MPD Foundation is pleased to once again host a booth at this year’s ASH convention.… Read More »AMERICAN SOCIETY OF HEMATOLOGY CONVENTION 2009